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a b s t r a c t
Simulation models are commonly used to address important health policy issues that
cannot be explored through experimental studies. These models are especially useful to
determine a set of strategies that result in a good value for money (cost-effectiveness).
Several mathematical models simulating the natural history of HPV and related diseases,
especially cervical cancer, have been developed to calculate a relative effectiveness and cost-
effectiveness of HPV vaccination and cervical cancer screening interventions. Virtually all
cost-effectiveness analyses identify HPV vaccination programmes for preadolescent girls to
be cost-effective, even for relatively low vaccination coverage rates. Routine vaccination of
preadolescent girls is the primary target population for HPV vaccination as it shows to pro-
vide the greatest health impact. Cost-effectiveness analyses assessing other vaccine target
groups are less conclusive. Adding additional age-cohorts would accelerate health benefits
in some years, although cost-effectiveness becomes less favourable as age at vaccination
increases. Including men in HPV vaccination programmes may be a less efficient strategy if
done at the expense of female vaccination coverage for reducing the burden of HPV in the
population. However, as the HPV vaccine price decreases, the cost-effectiveness of univer-
sal vaccination improves, becoming equally as efficient as female-only vaccination. Vaccine
price is a decisive factor in the cost-effectiveness analyses. The lower the price, the greater
the likelihood that vaccination groups other than the primary target would be considered
cost-effective.
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1. Background
Health economic evaluations, particularly cost-effectiveness
analyses (CEA), have become more prevalent in recent years
and are increasingly used to inform decisions on which new
products to include in the common services portfolios of the
national health care systems.1,2 At present, several health
technology assessment (HTA) agencies, such as the National
Institute for Health and Care Excellence (NICE, UK), the Phar-
maceutical Benefits Advisory Committee (PBAC, Australia) and
the Canadian Agency for Drugs and Technologies in Health
(CADTH), use cost-effectiveness as the most influential factor
in the HTA decision-making process.3 Together with the effec-
tiveness, safety and quality, cost-effectiveness evaluation is
one of the four cornerstones for the identification of best value
and resource allocation decision-making. That said, decision-
makers must also consider issues of equity, acceptability,
accessibility and affordability when drawing their conclu-
sions.
Over the past two decades, mathematical models sim-
ulating the natural history of human papillomavirus (HPV)
and related diseases, especially cervical cancer, have been
developed to assess health policy issues related to preven-
tion strategies. These models are commonly used to simulate
a relative effectiveness and cost, and then to calculate the
cost-effectiveness of HPV vaccination and cervical screening
interventions in relation to different parameters. Doing so
via experimental studies is virtually impossible for a num-
ber of reasons: first, the interest lies in the mid- to long-term
impact of these interventions; second, they target a group of
diseases with relatively low incidence which, moreover, can
take a very long time to manifest as precancerous lesions
after infection; and third, the parameter combinations pos-
sible for each intervention are numerous and varied, and
include the synergy between primary and secondary preven-
tion strategies.4
2. Cost-effectiveness analysis methodology
The primary goal of the CEA is the optimal allocation
of typically constrained resources to obtain the greatest
gain in population health.5 This approach provides a sys-
tematic and theoretical framework by which to compare
the relative costs and health effects of different interven-
tions and decide which of them represent good value for
money.6 The incremental cost-effectiveness ratio (ICER) is
the most common summary measure used in this regard,
defined as the difference in cost between two interventions
(e.g. A and B) divided by the difference in health effects:
ICER = (CostA − CostB)/(EffectA − EffectB), where said change in
health effects is usually measured in terms of the number
of life years (LYs) saved or the number of quality-adjusted
life years (QALYs) gained. As such, the ICER is frequently
expressed as the cost per LY saved or QALY gained.
In order to draw conclusions about which strategies
are cost-effective, the ICERs must be compared to a
pre-determined reference value or threshold below which
an intervention would be considered cost-effective. This
threshold serves to signpost policy-makers to which of the
possible interventions offer an efficient use of resources. It
can also be understood as the upper limit of what society
is willing to pay for an additional unit of health effect (e.g.
QALY).7 There is no consensus as to a universal ICER threshold,
with different HTA agencies defining country-specific bench-
marks to aid the decision-making process. The most extensive
discussion on the use of these values can be found in the
UK, where NICE has defined a range of £20,000–£30,000/QALY
gained.8 In the rest of Europe it ranges from country to coun-
try, from D 20,000/QALY gained in Spain to the D 50,000/QALY
gained reported in studies in Denmark and Germany.9–11 In the
USA interventions that cost less than $50,000/QALY gained or,
occasionally, between $50,000 and $100,000/QALY gained, are
considered to be good value for the resources invested.12 The
most universal threshold was used by the World Health Organ-
isation’s Commission on Macroeconomics and Health in its
2002 report on investing in health for economic development.
This heuristic recommends that an intervention be consid-
ered highly cost-effective if the ICER is less than the country’s
per capita gross domestic product (GDP) and cost-effective if
the ICER is less than three times the per capita GDP.13
3. HPV vaccination in preadolescent girls
The WHO-recommended primary target population is pread-
olescent girls aged 9–14 prior to becoming sexually active.
To date, numerous simulation models have been developed
to address the health and economic impact of introducing
HPV vaccination programmes for preadolescent girls. Despite
the diversity of the approaches, the different complexities
of the models parameters and assumptions, almost all eco-
nomic evaluations found such HPV vaccination programmes
to be cost-effective, even for relatively low vaccination cover-
age rates.14 Over the last ten years, prophylactic vaccination
against HPV in preadolescent girls has been introduced in
many countries, especially in high- and upper-middle-income
countries (Fig. 1).15
By 2014, around 47 million women worldwide had received
the full course of three doses and 59 million had received
at least one dose. In the more developed countries, these
figures represent a 33.6% and 43.3% coverage of female popu-
lation aged 10–20 years, respectively, while in less developed
countries this rate stands for 2.7% and 3.0%. The impact of
HPV vaccination has become increasingly evident in women
and heterosexual men, with reduced population prevalence
for targeted HPV genotypes, e.g. genital warts and low- and
high-grade cervical lesions, especially among women vacci-
nated before HPV exposure in countries with high vaccine
uptake.16 Pressure from international public health authori-
ties and HPV vaccine deals in 2013 mean that some non-profit
making non-governmental organisations can now purchase
HPV vaccines at around US$ 4.50 per dose, allowing a growing
number of girls to be protected in low and lower-middle-
income countries.17 It is estimated that 30 million girls will
be vaccinated in these countries by 2020 with international
assistance at different levels.
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Fig. 1 – Total number of vaccinated women and coverage as a percentage of the total female population, worldwide and by
level of development.
Data extracted from Bruni et al., 2016.15
Massive HPV vaccination of all preadolescent girls would
prevent millions of women dying from avertable cervical and
other HPV-related cancers, also protecting heterosexual men
through herd protection.
4. HPV vaccination in adolescent to
postadolescent girls and adult women
Postadolescent girls (15–26 years) and adult women (>26) are
considered by WHO as a secondary target population for
HPV vaccination, recommended only where this is feasible,
affordable, cost-effective and does not divert resources from
vaccination of the primary target population or from effective
cervical cancer screening programmes.18 Simulation models
for several developed countries have weighed up the costs
and health benefits of adding catch-up vaccine for postado-
lescent and older women to the vaccination of the primary
target.19–36 These studies tend to conclude that the effective-
ness and cost-effectiveness of HPV vaccination decrease as
age at vaccination increases.
In terms of their effectiveness, some models do report
health benefits for the vaccination of women aged 15 and over.
For instance, 34% of deaths from invasive cervical cancer can
be avoided by vaccinating women at age 40 (compared to 85%
if vaccinated at age 12).29 In another study, cervical cancer
cases were shown to drop by half if women are vaccinated
at age 25.28 The lifetime risk of cervical cancer is estimated
at 0.5% under current screening programmes with no vacci-
nation, 0.14% when girls are vaccinated at age 17, and 0.4%
when women are vaccinated at age 25.30 An interesting find-
ing in some models is that a temporary catch-up campaign for
older girls and younger women speeds up the reduction of cer-
vical cancer incidence by several years compared to baseline
vaccination.19,21,22,25,26,30,31,33,34 In the Netherlands, extending
the vaccination age range from 12–16 to 12–29 years could
bring forward a 5% reduction in cervical cancer cases by three
years.30 In terms of HPV 16/18 prevalence, a one-year catch-
up campaign targeting young women from just a few birth
cohorts could bring forward a 50% reduction by as much as
five years depending on the country (Fig. 2).33,34
In terms of cost-effectiveness, temporary catch-up vacci-
nation campaigns were found to be less favourable at older
ages, although the upper age limit varied widely from country
to country from 16 to 40 years old.19–23,25–32 These reported
differences may be due to a combination of multiple fac-
tors, such as the characteristics of the models and other
country-specific variables. Only one such model looked specif-
ically at the effect of HPV vaccination in women aged 30
or over, concluding that the likelihood of vaccination being
cost-effective for women aged 35 to 45 in the USA was 0%
with annual or biennial screening and less than 5% with
triennial screening, at thresholds considered good value for
money.24
However, most of the studies referenced above have been
rendered somewhat outdated due to rapid breakthroughs in
various aspects related to the HPV vaccine and HPV screen-
ing. For example, all models assume vaccination followed by
intensive screening, usually with intervals of 1–5 years, and
most of this screening is cytology-based, whether conven-
tional or liquid. However, the dramatically-reduced baseline
risk in vaccinated women observed, together with the tran-
sition from a cytology-based screening to one based on HPV
DNA testing, would allow the starting age for screening to be
raising and the screening intervals to be extended. Another
critical issue is that the baseline vaccine prices in these ear-
lier studies ranged from D 225 to D 400 for the three doses.
Today, the price has dropped by as much as 75% since the
vaccine was first licenced, especially when subjected to ten-
der procedures. Yet, although several studies demonstrate the
sensitivity of ICERs to vaccine price, only two studies from
the Netherlands specifically present results at near current
tender prices. One of these studies concludes that vaccina-
tion at D 45 per dose would remain cost-effective up to age
30.28 Fig. 3 shows how the ICER varies with vaccine price
at different vaccination ages.30 At all ages, we observe a
remarkable reduction in the cost-effectiveness ratio when the
vaccine price is reduced from 125D to 35D (72% decline),
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Fig. 2 – Effect of increasing the number of age cohorts vaccinated against HPV16/18 on time to reduction in the prevalence of
HPV infection in Italy.
Figure adapted from Bosch et al.38
Fig. 3 – Incremental cost-effectiveness ratios at different HPV vaccination ages and vaccine prices.
Data extracted from Bogaards et al., 2016.30
making vaccination very cost-effective at almost all ages ana-
lysed.
The latest results reporting high efficacy of vaccination in
older women,37 together with the reduction in vaccine price;
the arrival of vaccines targeting more HPV types, the ability
to reduce the number of doses, and the consolidation of HPV
DNA testing as the primary screening method presents a new
cervical cancer screening scenario,38 making vaccination of
postadolescent and adult women an attractive means of HPV
prevention.39,40
5. HPV vaccination in men
Women are at higher risk of presenting with HPV-related
cancers than men, although the proportion of these can-
cers in men is increasing. Worldwide, it is estimated that
around 60,000 HPV-attributable cancers are diagnosed in
men each year, along with a non-estimated but substan-
tial number of preventable cases of genital warts.41 As of
now, gender-neutral vaccination has been recommended in at
least 21 countries: Antigua and Barbuda, Argentina, Australia,
Austria, Bahamas, Barbados, Bermuda, Brazil, Canada, Croa-
tia, Czech Republic, Israel, Italy, Liechtenstein, New Zealand,
Norway, Panama, Serbia, Switzerland, the United States of
America and Turkmenistan. Other than penile cancer, men
are particularly at risk of head and neck cancers caused
by HPV, accounting for 80% of all cases. Anal cancer is
disproportionately high in men who have sex with men
(MSM), especially in those who are HIV-positive.41,42 HPV
vaccination in men can provide additional health bene-
fits, decreasing male risk of contracting genital warts and
developing HPV-related cancers, contributing to reduce HPV
transmission in general, and ensuring equity in protection
from HPV-associated diseases in both men and women. How-
ever, certain reservations emerge when assessing whether
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a universal HPV vaccination represents good value for
money.
To date, 21 studies starting in 2004 have examinated the
cost-effectiveness of universal vaccination, of which 12 have
been published in the last four years.10,11,23,27,35,43–58 The
general view is that increasing female coverage is a more effi-
cient strategy for reducing the burden of HPV in the population
than extending vaccination to males. However, models are
very sensitive to certain parameters, such as the inclusion
of some health outcomes, the duration of vaccine protection,
female coverage rates and the cost of the vaccine. Several stud-
ies agree that vaccinating males could be cost-effective where
female coverage is low or if the vaccine cost is substantially
reduced. As mentioned in previous sections, HPV vaccination
has undergone significant changes in recent years, which is
reflected in the parameters used in cost-effectiveness stud-
ies, with less optimistic coverage rates in females, prices well
below the original market values, and a greater range of poten-
tial health benefits. Fig. 4 shows a summary of the ICERs from
studies evaluating universal vaccination versus female-only
vaccination. For enhanced comparability, all ICERs were con-
verted to the same currency (euro, D ) using the exchange rates
from the corresponding indexed year. Panel A charts the size
of the ICERs (bubbles) against cost per vaccinated individual
(vertical axis) and female coverage (horizontal axis). By trac-
ing an imaginary boundary at the D 200 mark and another
at 60% coverage, we group the ICERs into three quadrants.
The highest ICERs are found in the upper right quadrant,
where both cost and coverage are also among the highest.
These correspond to some of the oldest studies; only 4 out of
the 14 studies in this quadrant were post-2013. In the other
two quadrants, where the ICERs either consider lower cov-
erages or lower vaccine costs, the size of the ICER is more
homogeneous. Panel B gives a box plot depicting the varia-
tion in the ICERs in the three quadrants. The highest mean
(D 156,206/QALY gained) and median (D 68,923/QALY) scores
are obtained for coverages greater than 60% and costs per
vaccinated individual of over D 200, followed by the scores
obtained when costs per vaccinated person fall below 200D
(mean D 39,480/QALY gained and median D 33,219/QALY) and
coverages fall below 60% (mean D 36,740/QALY gained and
median D 34,634/QALY).
As the HPV vaccine price decreases, the cost-effectiveness
of universal vaccination is more evident, becoming equally
as efficient as female-only vaccination. Some authors iden-
tify the cost from which universal vaccination would be
cost-effective. For instance, a study in New Zealand found
that extending vaccination to boys, based on a three-dose
schedule, would only be cost-effective when the price was
below NZ$ 125 per dose (approximately D 71 as in 2011).51
Another recent study from the Netherlands found that vac-
cination of boys based on a two-dose regime, would be
considered cost-effective when vaccination cost was below
D 65 per person, which was the actual cost in this country
from 2012 to 2014.58 An increase in the cost per vaccinated
individual from D 65 to D 350 would enhance the ICERs by
7.35. This study also reports that universal vaccination is
only slightly less efficient than increasing coverage among
girls.
6. HPV vaccination in MSM
The number of MSM that develop anal cancer as a result of
HPV infection has increased in all Western countries over the
last decades, especially among HIV-positive men.59 Accord-
ing to the Centres for Disease Control and Prevention (CDC),
men who have sex with men are about 17 times more likely to
develop anal cancer than men who only have sex with women
(MSW).60 HPV 16 and 18 are responsible for approximately 87%
of anal cancers, while the relative contribution of the 9-valent
vaccine types is 96%.41 It is estimated that 15% of MSW are
positive for HPV, compared to 60% of HIV-negative MSM and
90% of HIV-positive MSM.61,62
High vaccine coverage in the female population benefits
heterosexual males through herd immunity, where a substan-
tial decrease in the disease burden is related to genital warts.63
However, even if all females were immunised, HPV transmis-
sion in men would remain through MSM. Therefore, the MSM
population may be an additional target for routine HPV vacci-
nation. The immunogenicity of HPV vaccination in MSM aged
16–23 has already been proved in a randomised clinical trial.64
The first model to explore the potential effectiveness and
cost-effectiveness of the HPV vaccination of MSM was that of
Kim et al. in 2010.65 Their model assessed a healthy cohort of
MSM starting at age 12 years who were at risk of anal cancer
and genital warts during their lifetimes. Under different sce-
narios of age at vaccination, duration of vaccine protection,
HPV and HIV exposure and anal cancer incidence, cost-
effectiveness ratios remained lower than the aforementioned
thresholds of $50,000 and $100,000/QALY gained. Assuming
50% coverage, HPV vaccination of MSM at age 12 years had a
cost-effectiveness ratio of $15,290/QALY gained as compared
to no vaccination; $19,160/QALY gained if MSM were vacci-
nated at age 26 and assuming 10% exposure to HPV 16, 18,
6 and 11; and $37,830/QALY gained assuming 50% exposure.
Using a dynamic model, Lin et al. evaluated the impact of offer-
ing vaccination to MSM who visited genitourinary medicine
clinics (GUM).66 Substantial declines in anogenital warts and
male HPV-related cancer incidence were estimated by offer-
ing HPV vaccination to MSM aged 16–40 who attended GUM
clinics. Specifically, anogenital warts incidence was lowered
by 35% within five years (by 15% where only HIV-positive MSM
were vaccinated) and HPV-related cancer incidence dropped
by 55% within 100 years (40% where only HIV-positive MSM
were vaccinated). The authors also indicated that HPV vacci-
nation of this group could be cost-effective if all MSM up to
age 40 were vaccinated at a cost of £48 per dose or if only
HIV-positive MSM were vaccinated at maximum cost of £96.50
per dose. However, an analysis with a compartmental model
for Australia concluded that the greatest health benefits for
MSM would only be achieved by targeting all boys, and that
a vaccination programme for young MSM aged 15–26 years in
addition to the boys programme would only be cost-effective
if implemented immediately.67
HPV vaccination as a secondary strategy for the preven-
tion of recurrent high-grade anal intraepithelial lesions and
invasive anal cancer was assessed for both HIV-negative and
HIV-positive men aged 27 and above.68–70 For both, the risk of
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Fig. 4 – Summary of ICERs from studies including universal vaccination versus female-only vaccination. Panel A: Bubble
diagram of ICERs (bubble) plotted against cost per vaccinated individual and female vaccination coverage. Panel B: Box-plot
of ICERs in three groups combining female vaccination coverage and cost per vaccinated individual. All studies report
figures in euros per QALY gained, except one where they are given in euros per life-year gained.
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recurrence and subsequent progression to invasive anal can-
cer decreased by around 60% as compared to no vaccination.
Such intervention would be cost-effective for HIV-negative
men and cost-saving for HIV-positive men.
7. HPV vaccination in childhood
Although HPV infection predominantly affects adults, HPV-
related diseases in the oropharyngeal and anogenital mucosa
of infants and children have also been widely reported.
However, the prevalence of and progression to HPV-related
lesions is unclear. HPV has been shown to be transmitted
in several modes including perinatal transmission, auto- and
hetero-inoculation, sexual abuse and indirect transmission
via fomites.71
Irrespective of the HPV burden in infants and children, HPV
vaccination in childhood might be considered a significant
step forward for the overall reduction of HPV-related dis-
eases and essential for achieving global immunisation.72,73 It
is estimated that coadministration of HPV vaccine with other
vaccines such as diphtheria, tetanus, pertussis, meningo-
coccal conjugate, and influenza vaccine could increase HPV
vaccine coverage for the first dose to 90%.74 It has been demon-
strated to be safe and effective in children as young as 9,
but no clinical trials are available for younger age groups, nor
are there any models specifically evaluating the effectiveness
and cost-effectiveness of vaccination in childhood. Only one
study from 2004, before vaccines became licensed and primar-
ily focusing on vaccination in children aged 12, considered the
vaccination of infants as a possible strategy.43 The number of
lifetime cervical cancer cases was estimated to be the same
when vaccinating infants as when vaccinating 12-year-olds,
because it was held that most infections occur after age 12.
Assuming 70% coverage and a booster dose after 10 years, the
model suggests that a vaccination programme focusing on 12-
year-olds would be more cost-effective than one focusing on
infants.
8. Other future directions in HPV
vaccination
Besides identifying which target groups are more favourable
for vaccination, other issues have a critical impact on cost-
effectiveness, such as the dosing schedule, the new generation
of vaccines against more HPV types and protection against
HPV-associated diseases other than cervical cancer.
Some studies suggest that two doses of the HPV vac-
cine (sometimes even one dose) may be as protective as
three doses.75,76 The most important factor influencing cost-
effectiveness in this scenario is the lower cost of HPV
vaccination, which will cut total health expenditure. Lower
doses would improve uptake, increase competition rates and
likely lead to fewer adverse events. Some models have evalu-
ated the impact of different dosing schedules for the three
vaccines.11,36,50,77–79 The results from a model for Canada
show that two doses of the bivalent (2-valent: HPV 16 and
18) vaccination administered to preadolescent girls as com-
pared to no vaccination would be cost-effective if vaccine
protection lasted over 10 years.50 The third dose would not be
cost-effective if protection lasted over 30 years for the 2-valent
vaccine and over 20 years for the nonavalent (9-valent: HPV
6, 11, 16, 18, 31, 33, 45, 52, and 58) vaccine.50,80 These findings
are very consistent with results from the UK, which concluded
that a third dose of the quadrivalent (4-valent: HPV 6, 11, 16,
and 18) vaccine would need to be priced substantially lower
to be cost-effective if two doses provided the same protection
as three doses for over 20 years.36 In 2014, the WHO recom-
mended a 2-dose schedule when vaccination series started at
<15 years and many countries are now using this schedule for
this age group.18
The 9-valent vaccine was approved by the US Food and
Drug Administration in December 2014 and by the European
Medicine Agency in June 2015. Two doses of this vaccine pro-
tect against some 90% of all HPV-positive cancers, over 80%
of high-grade precancerous lesions and 90% of genital wart
and recurrent respiratory papillomatosis cases caused by HPV
types 6/11.41,81 Economic evaluations in the USA, Italy and
Germany comparing the 9-valent with the 4-valent HPV vac-
cine suggest that the 9-valent could reduce the health burden
from cervical cancer and HPV-related diseases to a greater
extent than the 4-valent, which would make it highly cost-
effective and even cost-saving in some cases.56,57,82 However,
to provide three doses of the 9-valent vaccine to females
aged 13–18 who had previously completed a course of the 4-
valent vaccine exceeded the upper limit of the USA threshold
($100,000/QALY).83
Generally available economic evaluations take different
health outcomes into account, from cervical cancer to the
entire range of HPV-related diseases. Cost-effectiveness ratios
can underestimate the potential of HPV vaccination if not all
HPV-related diseases are included. Several articles have quan-
tified these differences, progressively including more health
outcomes in the model. A recent study assessing the influ-
ence of non-cervical HPV-associated diseases on the ICERs
calculated for HPV vaccination concluded that the mean ICERs
were 2.85 times more favourable for female-only vaccina-
tion and 3.89 times more favourable for universal vaccination
when other HPV-related diseases are included.84 One study
in Canada evaluated the potential cost-effectiveness of HPV
vaccination for boys aged 12 in relation to the prevention of
oropharyngeal cancer.85 The authors concluded that 4-valent
HPV vaccination in males for the prevention of HPV-related
oropharyngeal cancer could result in QALY gains and cost sav-
ings as compared to no vaccination.
9. Conclusions
Based on the above analysis, HPV vaccination of preadoles-
cent girls emerges as a very cost-effective strategy to reduce
the health and economic burden of HPV-related diseases.
The greatest impact would be obtained by routinely vacci-
nating preadolescent girls prior to their becoming sexually
active, where high coverage is necessary to achieve sub-
stantial herd effects. The vaccination of catch-up cohorts
would accelerate the observed health benefits, although cost-
effectiveness becomes less favourable as age at vaccination
increases. However, coverage of female-only vaccination has
been suboptimal in many settings. Good female coverage
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provides protective effects to heterosexual men. Thus, includ-
ing men in HPV vaccination programmes would ensure equity
in protection from HPV-associated disease both for men and
women, and would extend the benefits to MSM who do not
benefit from the herd effects of female-only vaccination. This
would make MSM population a potential additional target
for routine HPV vaccination, given that this has been proven
cost-effective. However, the feasibility of this strategy is ques-
tionable, since early identification of this specific population
is difficult. Therefore, universal vaccination might be the only
way to protect all men, rather than relying on the benefits of
herd protection.
However, the cost-effectiveness of most of these strate-
gies depends on vaccine cost and other vaccine and model
assumptions. Vaccine price is the most decisive factor. Indeed,
the lower the price, the greater the likelihood that vaccinat-
ing groups other than the primary target would be considered
cost-effective in relation to alternative uses of healthcare
resources. Based on the simulation models, the inclusion of
all HPV-related outcomes, reduced dosing schedules and the
new generation of HPV vaccines into the current vaccination
scenario, as well as lower vaccine prices, is expected to boost
cost-effectiveness, which may contribute to greater financial
support for massive universal HPV vaccination programmes
by governments.
Mathematical models will continue to be used in the
future to address important health policy issues that cannot
be to explored through experimental studies. These models
are especially useful to determine which of a set of strate-
gies is good value for money. The model-building process is
important and labour-intensive. Modellers should make the
structure and content of the model transparent to researchers
and health decision-makers, as well as test the assumptions
using sensitivity analyses and model validation. As in all
research, simulation models can sometimes produce inaccu-
rate results and can need to be repeated as and when more
data becomes available. However, rigorous and reliable results
can undoubtedly help make informed decisions about health-
care practices and resource allocation.
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